¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"primary signal system"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 12 ÆäÀÌÁö: 15
  • ¿µ¹®
    ÇѱÛ
  • static system
    Á¤Áö°è
  • stereotactic system
    Á¤À§°íÁ¤±â
  • subcortical descending system
    °ÑÁú¹ØÇÏÇà°è, °ÑÁú¹Ø³»¸²°èÅë
  • superficial musculo-aponeurotic system
    ¾ó±¼³ÎÈûÁÙ°èÅë
  • to and fro absorbent system
    ¿Õº¹Èí¼ö½Äȸ·Î
  • transdermal drug delivery system
    °æÇǾ๰Àü´Þü°è
  • urinary system
    ºñ´¢°èÅë
  • urogenital system
    ºñ´¢»ý½Ä°èÅë
  • value system
    °¡Ä¡Ã¼°è
  • vascular system
    Ç÷°ü°èÅë
  • vegetative nervous system
    (¢¡autonomic nervous system) ÀÚÀ²½Å°æ°èÅë
  • workload recording system
    ÀÛ¾÷ºÎÇϱâ·Ïü°è
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 15
  • ¿µ¹®
    ÇѱÛ
  • primary focus
    ¿øº´¼Ò
  • primary follicle
    ÀÏÂ÷³­Æ÷, ¿ø½Ã³­Æ÷(ê«ã·Õ°øà), ¿ø½Ã¿©Æ÷(¡­æ¤øà).
  • primary follicle
    ÀÏÂ÷³­Æ÷
  • primary gain
    ÀÏÂ÷(Àû) À̵æ(ìéó­îÜì¦Ôð).
  • primary germ layer
    ÀÏÂ÷¹è¿±(¡­ÛÏç¨).
  • primary glaucoma
    ¿ø¹ß³ì³»Àå(ê«Û¡ÖàÒ®î¡).
  • primary glaucoma ³ª g. primarium
    ¿ø¹ß³ì³»Àå(ê«Û¡ÖàÒ®î¡)
  • primary glomerular insufficiency
    ¿ø¹ß(¼º) »ç±¸Ã¼ºÎÀü(¡­ÞêϹô÷ÝÕîï).
  • primary glomerular insufficiency
    ¿ø¹ß(¼º) »ç±¸Ã¼ºÎÀü(ê«Û¡(àõ) ÞêϹô÷ÝÕîï)
  • primary hair =lanugo
    ÀÏÂ÷¸ð(ìéó­Ù¾).
  • primary hair follicle
    ÀÏÂ÷ÅÐÁÖ¸Ó´Ï
  • primary hemorrhage
    ¿ø¹ß(¼º) ÃâÇ÷(ê«Û¡(àõ) õóúì), ÀÏÂ÷ÃâÇ÷(ìéó­õóúì)
  • primary hepatic carcinoma
    ¿ø¹ß(¼º) °£¾ÏÁ¾(ê«Û¡(àõ) ÊÜäßðþ)
  • primary herpetic gingivostomatitis
    ¿ø¹ß(¼º) Ç츣Æä½º(¼º) Ä¡Àº±¸³»
  • primary hydrocephaly
    ¿ø¹ß(¼º) ¼öµÎÁõ.
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 15
  • ¿µ¹®
    ÇѱÛ
  • primary polycyth(a)emia
    ¿ø¹ß(¼º) ÀûÇ÷±¸Áõ°¡(Áõ)(¡­îåúìϹñòÊ¥ñø).
  • primary polycyth(a)emia
    ¿ø¹ß(¼º) ÀûÇ÷±¸Áõ°¡(Áõ)(ê«Û¡(àõ) îåúìϹñòÊ¥(ñø))
  • primary position
    Á¦ÀϾÈÀ§, Á¦ÀÏ´«À§Ä¡
  • primary position (of eye)
    Á¦ÀϾÈÀ§(ð¯ìéäÑêÈ)
  • primary position of the eye
    Á¦ÀϾÈÀ§(ð¯ìé äÑêÈ), Á¦ÀÏ´«À§Ä¡
  • primary posterolateral sclerosis
    ¿ø¹ß(¼º) ÈÄ¿ÜÃø»è°æÈ­(Áõ).
  • primary posterolateral sclerosis
    ¿ø¹ß(¼º) ÈÄ¿ÜÃø»è°æÈ­(Áõ)(ê«Û¡(àõ) ý­èâö°ßãÌãûù(ñø))
  • primary pregnancy
    ÀÏÂ÷ÀÓ½Å
  • primary pulmonary hypertension
    ¿ø¹ß(¼º) Æó°íÇ÷¾ÐÁõ(¡­øËÍÔúìäâñø).
  • primary pulmonary hypertension
    ¿ø¹ß(¼º) Æó°íÇ÷¾ÐÁõ(ê«Û¡(àõ) øËÍÔúìäâñø)
  • primary pulmonary lobule
    ÀÏÂ÷ÇãÆÄ¼Ò¿±
  • primary ray
    ÀÏÂ÷¼±
  • primary reinforcer
    ÀÏÂ÷Àû¡¡°­È­¹°£¨Ë­ûùÚª£©
  • primary sampling unit
    ÀÏÂ÷ÃßÃâ´ÜÀ§(ÊÙ̧̧ËÀËô).
  • primary sclerosing cholangitis
    ¿ø¹ß(¼º) °æÈ­¼º ´ã°ü¿°(¡­ÌãûùàõÓÅηæú).
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 15
LPC late positive component; lipocortin; longitudinal primary care [program]; lysophosphatidylcholine
MPM malignant papillary mesothelioma; medial pterygoid muscle; minor psychiatric morbidity; multiple pri...
OPM occult primary malignancy; Office of Personnel Management; ophthalmoplegic migraine
PACC primary ambulatory care center; promoting aphasics' communicative competence
PAD pain and distress; patient surface axis depth; percutaneous abscess drainage; percutaneous automated...
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 15
PAPS Primary Antiphospholipid Syndrome
PBC Primary Biliary Cirrhosis
PCNSL Primary CNS lymphoma
PC Primary Care
PCC Primary Care Centre
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 15
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • sensory modulatory system
    °¨°¢ Á¶Àý°è
  • serotonergic endogenous analgesic system
    ¼¼·ÎÅä´Ñ ³»¿ø¼º ÁøÅë°è
  • shift system
    ±³´ëÁ¦ ±Ù¹«
    8½Ã°£ ÀÌ»óÀÇ ³ëµ¿À» ÇÊ¿ä·Î ÇÏ´Â Á÷Àå¿¡¼­ Á¶·Î ³ª´©¾î ÀÏÇÏ´Â Á¦µµ.
  • sodium transport system
    ³ªÆ®·ý ¿î¹Ý°è
  • stomatognathic system
    ±¸°­¾Ç°è, ±¸°­ ÇϾǰè, ¾Ç±¸°­°è
    Ä¡¾Æ, ¾Ç°ñ, ÃøµÎÇϾǰüÀý, ÀúÀÛ±Ù »çÀÌÀÇ ±â´ÉÀû ¹× ÇØºÎÇÐÀû °ü°è.
  • superficial musculoaponeurotic system
    Ç¥Ãþ ±Ù°Ç¸· ü°è
  • supraopticohypophyseal system
    ½Ã°¢ ±³Â÷ À§³úÇÏ ¼öü°è, ½Ã°¢·ÎÀ§ ³úÇÏ ¼öü·Î
  • sympathetic nerve system
    ±³°¨ ½Å°æ°è
  • sympathetic nervous system activity
    ±³°¨½Å°æ°è Ȱ¼º
  • sympatheticoadrenomedullary system
    ±³°¨½Å°æ ºÎ½Å ¼ÓÁú°è
  • system
    °èÅë, ü°è, ±â°ü°è, °è, Àü½Å
  • system lupus erythematosus
    Àü½Å¼º È«¹Ý¼º ³¶Ã¢
  • TNM-system
    TNM °è
  • to and fro absorbent system
    ¿Õº¹ Èí¼ö¹ý
  • trigonal system
    »ï°¢Çü°è
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 15
cell-free system <cell culture, molecular biology> Any system in which a normal cellular reaction is reconstituted in the absence of cells for example in vitro translation systems that will synthesise protein from mRNA using a lysate of rabbit reticulocytes or wheat germ.
A fractionated cell extract that maintains a biological function. A subcellular fraction isolated by ultracentrifugation or other separation techniques must first be isolated so that a process can be studied free from all of the complex side reactions that occur in a cell. The cell-free system is therefore widely used in cell biology.
(12 Dec 1998)
renal portal system An arterial portal system, in which efferent glomerular arterioles receive blood from the capillaries of the renal glomeruli and carry it to the peritubular capillary plexus surrounding the proximal and distal convoluted tubules.
Synonym: hypothalamohypophysial portal system.
(05 Mar 2000)
p blood-group system A blood group related to the abo, lewis and I systems. at least five different erythrocyte antigens are possible, some very rare, others almost universal. Multiple alleles are involved in this blood group.
(12 Dec 1998)
renin-angiotensin-aldosterone system The hormones, renin, angiotensin, and aldosterone work together to regulate blood pressure. A sustained fall in blood pressure causes the kidney to release renin. This is converted to angiotensin in the circulation. Angiotensin then raises blood pressure directly by arteriolar constriction and stimulates adrenal gland to produce aldosterone which promotes sodium and water retention by kidney, such that blood volume and blood pressure increase.
(05 Mar 2000)
renin-angiotensin system <physiology> A system consisting of renin, angiotensin-converting enzyme, and angiotensin II.
Renin, an enzyme produced in the kidney, acts on angiotensinogen, an alpha-2 globulin produced by the liver, forming angiotensin I. The converting enzyme contained in the lung acts on angiotensin I in the plasma converting it to angiotensin II, the most powerful directly pressor substance known. It causes contraction of the arteriolar smooth muscle and has other indirect actions mediated through the adrenal cortex.
(25 Jun 1999)
centimeter-gram-second system The scientific system of expressing the fundamental physical units of length, mass, and time, and those units derived from them, in centimeters, grams, and seconds; currently being replaced by the International System of Units based on the meter, kilogram, and second.
(05 Mar 2000)
reproductive system In women, the organs that are directly involved in producing eggs and in conceiving and carrying babies.
(12 Dec 1998)
pedal system Efferent fibres connecting the forebrain with more caudal structures.
(05 Mar 2000)
central nervous system <anatomy, neurology> Pertaining to the brain, cranial nerves and spinal cord. It does not include muscles or peripheral nerves.
In invertebrates, the central nervous system is composed of the segmental ganglia of the ventral nerve cord together with the fused ganglia or brain at the anterior end.
Acronym: CNS
(12 Jan 1998)
central nervous system agents A class of drugs producing both physiological and psychological effects through a variety of mechanisms. They can be divided into "specific" agents, e.g., affecting an identifiable molecular mechanism unique to target cells bearing receptors for that agent, and "non-specific" agents, those producing effects on different target cells and acting by diverse molecular mechanisms. Those with non-specific mechanisms are generally further classed according to whether they produce behavioural depression or stimulation. Those with specific mechanisms are classed by locus of action or specific therapeutic use.
(12 Dec 1998)
central nervous system depressants A very loosely defined group of drugs that tend to reduce the activity of the central nervous system. The major groups included here are ethyl alcohol, anaesthetics, hypnotics and sedatives, narcotics, and tranquillising agents (antipsychotics and antianxiety agents).
(12 Dec 1998)
central nervous system infections Diseases of the central nervous sytem collectively, caused by pathogenic organisms.
(12 Dec 1998)
central nervous system neoplasms Neoplasms located in the brain, spinal cord, or meninges.
(12 Dec 1998)
central nervous system stimulants A loosely defined group of drugs that tend to increase behavioural alertness, agitation, or excitation. They work by a variety of mechanisms, but usually not by direct excitation of neurons. The many drugs that have such actions as side effects to their main therapeutic use are not included here.
(12 Dec 1998)
glycogen debranching enzyme system 1,4-alpha-d-glucan-1,4-alpha-d-glucan 4-alpha-d-glucosyltransferase/dextrin 6 alpha-d-glucanohydrolase. An enzyme system having both 4-alpha-glucanotransferase (ec 2.4.1.25) and amylo-1,6-glucosidase (ec 3.2.1.33) activities. As a transferase it transfers a segment of a 1,4-alpha-d-glucan to a new 4-position in an acceptor, which may be glucose or another 1,4-alpha-d-glucan. As a glucosidase it catalyses the endohydrolysis of 1,6-alpha-d-glucoside linkages at points of branching in chains of 1,4-linked alpha-d-glucose residues. Amylo-1,6-glucosidase activity is deficient in glycogen storage disease type III.
(12 Dec 1998)
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 15
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 15
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 15
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 15
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 15
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 15
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 15
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 15
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 15
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 15
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 15
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 15
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 15
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 15
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 15
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 15
  • ¿µ¹®
    ÇѱÛ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 15
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 15
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 15
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 15
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 15
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 15
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 15
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 15
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 15
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 15
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 15
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 15
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 15
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 15
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 15
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 15
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 15
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 15
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 15
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 15
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 15
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 15
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 15
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 15
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 15
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 15
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 15
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 15
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 15
  • ¿µ¹®
    ÇѱÛ
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 15
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 15
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 15
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 15
ÅëÇÕ°Ë»ö ¿Ï·á